Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 2;29(1):1326–1334. doi: 10.1080/10717544.2022.2069301

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — The PDS ocular implant, ancillary devices, and position in situ. (A) PDS implant showing four key features: an extrascleral flange that anchors the implant in the sclera, a self-sealing septum that allows for implant refills, an implant body that contains the drug reservoir for the customized formulation of ranibizumab, and the porous titanium RCE that controls the rate of ranibizumab diffusion into the vitreous. (B) Insertion tool assembly to facilitate handling of the implant during the initial filling and insertion procedures, and explant tool (lower image) to grasp and securely hold the implant flange during the explant procedure (if explantation is clinically indicated). (C) Initial fill needle to fill the implant with ranibizumab before insertion. (D) Refill needle to refill-exchange, in situ, the implant with ranibizumab. (E–G) show the PDS implant in situ. Images from a PDS-implanted patient showing (E) eye in primary position (implant not visible), (F) eye looking down with the PDS implant septum visible, and (G) eye looking up with implant visible through dilated pupil. Copyright 2021 F. Hoffmann-La Roche Ltd., all rights reserved. Used with permission. Abbreviations: PDS: Port Delivery System with ranibizumab; RCE: release control element.